Stocks News

LAST PRICE
124.9800
TODAY'S CHANGE (%)
Trending Down-0.0200 (-0.0160%)

Bid / Lots
124.9200/ 1
Ask / Lots
125.1300/ 6
Open / Previous Close
125.1800 / 125.0000
Day Range
Low 124.4900
High 127.0000
52 Week Range
Low 109.7700
High 157.9799
Volume
411,575
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 7, 2024
- Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by PR Newswire
  8:30AM ET on Thursday Nov 07, 2024 by PR Newswire
  Companies Mentioned: NBIX
  -- Data Support Positive Impact ofINGREZZA in People With Huntington's Disease Chorea
  -- Findings Presented at the 2024 Annual Meeting of the Huntington Study Group
  Neurocrine Biosciences, Inc.(Nasdaq: NBIX)today presented subgroup analyses and data from the KINECT(R)-HD study showing the impact of INGREZZA(R) (valbenazine) capsules on emotional health and psychiatric stability in patients with chorea associated with Huntington's disease. The subgroup analysis showed consistent efficacy in reducing chorea compared to placebo across all identified subgroups, categorized by demographics and baseline assessment scores. A separate data analysis showed improvements in some aspects of emotional health with no worsening of psychiatric symptoms. This research will be shared at the 2024 Annual Meeting of the Huntington Study Group in Cincinnati.
- Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself.
Nov 5, 2024
- Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire
  4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire
  Companies Mentioned: NBIX
  2024 UBS Global Healthcare Conference on November 12
  Stifel 2024 Healthcare Conference on November 18
  Jefferies London Healthcare Conference on November 19
  Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at three upcoming investor conferences in November.
- Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: NBIX
  
  Neurocrine Biosciences to Participate at Investor Conferences in November
  
  PR Newswire
  
  SAN DIEGO, Nov. 5, 2024
  
  2024 UBS Global Healthcare Conference on November 12
Nov 4, 2024
- Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Monday Nov 04, 2024 by PR Newswire
  8:30AM ET on Monday Nov 04, 2024 by PR Newswire
  Companies Mentioned: NBIX
  -- Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients
  Neurocrine Biosciences, Inc.(Nasdaq: NBIX)presented data from more than 300 patients diagnosed with tardive dyskinesia and treated with INGREZZA(R) (valbenazine) capsules. These data showed significant improvements in functional, social, emotional and health-related quality of life measures in Phase 3 and 4 studies and improvements in functional, social, independence, emotional and physical aspects of patients' lives and antipsychotic adherence in real-world practice. This research was shared at the 2024 Psych Congress in Boston.

Today
- The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Medpace Holdings Inc's Possible Securities Law Violations, from 1 hour ago by Accesswire
  1 hour ago by Accesswire
  Companies Mentioned: MEDP
- The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Medpace Holdings Inc's Possible Securities Law Violations, from 1 hour ago by Dow Jones
  1 hour ago by Dow Jones
  Companies Mentioned: MEDP
- MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 3 hours ago by Dow Jones
  3 hours ago by Dow Jones
  Companies Mentioned: MEDP
- MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 3 hours ago by Newsfile
  3 hours ago by Newsfile
  Companies Mentioned: MEDP
Yesterday
- Alert of Investigation of MEDP: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 18 hours ago by Accesswire
  18 hours ago by Accesswire
  Companies Mentioned: MEDP
- Alert of Investigation of MEDP: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: MEDP
- Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm, from 23 hours ago by Accesswire
  23 hours ago by Accesswire
  Companies Mentioned: MEDP
- MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ:MEDP) Investors with Significant Losses to Contact the Firm, from 23 hours ago by Accesswire
  23 hours ago by Accesswire
  Companies Mentioned: MEDP
- Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm, from 11:47AM ET on Thursday Nov 21, 2024 by Dow Jones
  11:47AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: MEDP
- MEDP Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 9:46AM ET on Thursday Nov 21, 2024 by Newsfile
  9:46AM ET on Thursday Nov 21, 2024 by Newsfile
  Companies Mentioned: MEDP

Neurocrine Biosciences Inc
NASDAQ:NBIXUnited States

Search Criteria

Nov 7, 2024

Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by PR Newswire

Neurocrine Biosciences Presents New KINECT(R)-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 5, 2024

Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by PR Newswire

Neurocrine Biosciences to Participate at Investor Conferences in November, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones

Nov 4, 2024

Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA(R) (valbenazine) Capsules, from 8:30AM ET on Monday Nov 04, 2024 by PR Newswire

Peers Headlines

Today

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Medpace Holdings Inc's Possible Securities Law Violations, from 1 hour ago by Accesswire

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Medpace Holdings Inc's Possible Securities Law Violations, from 1 hour ago by Dow Jones

MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 3 hours ago by Dow Jones

MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (MEDP) Investors with Significant Losses to Contact the Firm, from 3 hours ago by Newsfile

Yesterday

Alert of Investigation of MEDP: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 18 hours ago by Accesswire

Alert of Investigation of MEDP: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 18 hours ago by Dow Jones

Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm, from 23 hours ago by Accesswire

MEDP Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ:MEDP) Investors with Significant Losses to Contact the Firm, from 23 hours ago by Accesswire

Medpace Holdings, Inc. Is Being Investigated For Fraud And Investors With Losses Are Encouraged To Reach Out To The Schall Law Firm, from 11:47AM ET on Thursday Nov 21, 2024 by Dow Jones

MEDP Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm, from 9:46AM ET on Thursday Nov 21, 2024 by Newsfile